News

This assay is designed to help determine factor IX activity levels in the plasma of individuals with hemophilia B who are two…

If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A PDUFA Target Action Date is March 31, 2023….

Pfizer had positive results from the Phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult…

It’s the most prevalent, yet lesser known, bleeding disorder. Here’s what you need to know about VWD. by: Michael Hickey Of the…

NHF’s Judith Graham Pool Postdoctoral Research Fellowship program turns 50. We spoke with five awardees about how the fellowship shaped their careers….

by: Donna Behen Blood Safety Millions of Americans who have or are at high risk for heart disease regularly take anti-platelet drugs…

Telemedicine provided vital access to blood and bleeding disorders care during the pandemic. What does the future hold for this technology? Remote…

New this year: Purchase tickets to multiple cities, at one time, and receive discounted pricing.  Are you as excited as we are…

The Centers for Disease Control and Prevention’s (CDC) Division of Blood Disorders offers an ongoing Public Health Webinar Series on Blood Disorders. The…

GLHF would not be able to put on several programs and events throughout the year without the help of our incredible volunteers….

The Food and Drug Administration (FDA) has announced that FDA’s Rare Disease Day is Monday, February 27. Registration is open for this…

On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is…

These updates were presented during the International Society on Thrombosis and Haemostasis (ISTH) Congress in London. Sanofi recently shared new clinical trial…

Diabetes and infection with human immunodeficiency virus (HIV) increase the risk of high blood pressure (hypertension) among men with hemophilia, a U.S. study…

Pain is a serious medical concern in America.  For those with a bleeding disorder, pain as a result of a bleeding episode…

Insights from historian Dr. Helen Rappaport – NHF sat down with historian Dr. Helen Rappaport to learn more about how hemophilia impacted…

The company’s investigational gene therapy has been developed for individuals with severe or moderately severe hemophilia B. The UK-based biotechnology company Freeline…

COVID-19 vaccine for children ages 5-11 receives final approval. “NHF applauds the CDC’s recommendation of the Pfizer-BioNTech COVID-19 vaccine for children 5…

by: Laurie Kelley When you submit an insurance form for coverage, have you ever been denied?   What should you do if you’ve already…

Healthcare professionals, register now for February CDC webinar on new NHF-McMaster hemophilia care guidelines. NHF is excited to announce that the Centers for…

by: Sen. André Jacque and Rep. Paul Tittl | April 17, 2021 The health and economic impacts of the ongoing pandemic have…

The recent American Society of Gene & Cell Therapy (ASGCT) Virtual Meeting featured updates from the phase III HOPE-B clinical trial of…

Kevin Mills, PhD has joined the National Hemophilia Foundation as chief scientific officer. A graduate of University of Colorado Boulder, MIT, and…

Early studies have indicated that women who are pregnant or breastfeeding who have received a COVID-19 vaccination can pass antibodies along to…